A novel treatment for heart failure targets myocardial fibrosis

01-ago-2021 | Revista: Nature Medicine

John G F Cleland 1, Pierpaolo Pellicori 2, Arantxa González 3 4

A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.

CITA DEL ARTÍCULO Nat Med. 2021 Aug;27(8):1343-1344. doi: 10.1038/s41591-021-01457-9.

ver publicación en pubmed

Nuestros autores

Dra. Arantxa González Miqueo Ver Curriculum

Investigadora | Investigadora principal Grupo de Investigación en Insuficiencia Cardíaca